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Abstract Mutations of the Fms-like tyrosine kinase 3
(FLT3) can be detected in a significant number of acute
myeloid leukemias (AML). Seventy-five cases of acute
myeloid leukemia were evaluated for FLT3-internal tandem
duplications (ITD) by polymerase chain reaction. Paraffin-
embedded formalin-fixed trephine biopsies of these cases
were evaluated for expression of phosphorylated signal
transducer and activator of transcription 1 (pSTAT1), pSTAT3,
and pSTAT5. Specific expression of pSTAT5 was proven in
leukemic blasts in situ by double staining with a blast-specific
marker. Expression of pSTAT5 in ≥1% of blasts was highly
predictive of FLT3-ITD. Neither expression of pSTAT1
nor pSTAT3 were associated with FLT3 mutations.
Altogether we conclude that pSTAT5 expression can
precisely be assessed by immunohistochemistry in rou-
tinely processed bone marrow trephines, STAT5 is highly
likely the preferred second messenger of FLT3-mediated
signaling in AML, and expression of pSTAT5 is predictive
of FLT3-ITD.
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Introduction
The gene for Fms-like tyrosine kinase 3 (FLT3) encodes a
receptor tyrosine kinase that plays an important role in
hematopoiesis [1]. FLT3 is recurrently targeted by genetic
aberrations in leukemias. FLT3 mutations may be internal
tandem duplications (ITD) of the exons encoding for the
juxtamembrane domain or point mutations in the tyrosine
kinase domain [2]. FLT3 may possibly be activated by
translocations as well [3, 4]. FLT3-ITD can be found in
20% to 30% of patients with de novo acute myelogenous
leukemia (AML) [5–8]. It leads to the disruption of a
repressor sequence in the juxtamembrane domain of the
FLT3 gene, which causes a constitutive autophosphoryla-
tion of the receptor [9]. This in turn promotes cell
proliferation and inhibits apoptosis in leukemic blasts [9,
10]. Alterations of FLT3 seem to be of significant
consequence in the clinical behavior of AML [5, 6, 8,
11]. Though the most recent edition of the World Health
Organization (WHO)-Classification of Tumours of Haema-
topoietic and Lymphoid Tissues introduced the incorpora-
tion of genetic abnormalities into diagnostic algorithms for
the diagnosis of AML, FLT3 mutations were not included
as a defining criterion for any distinct entity since they
frequently accompany other well-recognized genetic
lesions. However, in cases of cytogenetically normal
AML and in AML with myelodysplasia-related changes,
assessment of FLT3 mutations is recommended, and, if
present, the abnormality should be noted along with the
diagnosis [11].
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The signal transducers and activators of transcription
(STAT) gene family consist of seven proteins [12]. STAT-
mediated signal transduction pathways influence neoplastic
processes on a broad basis by perturbing control over
survival, differentiation, proliferation, and apoptosis [13].
Aberrant activation of STAT3 and STAT5 (less often
STAT1) has been demonstrated in diverse groups of
neoplasms, including AML [14–16]. Activation of STAT
is caused by tyrosine phosphorylation followed by the
consecutive translocation of pSTAT into the nucleus [17].
In normal hematopoiesis, STAT5 is activated by receptor
ligation of FLT3 to its ligand as well as by several other
cytokines [18, 19], thus STAT5 being the preferred second
messenger of FLT3-mediated signaling.
The aim of this study was to assess protein expression of
pSTAT1, pSTAT3, and pSTAT5 in a well-defined set of
AML with known status of the FLT3 gene, in order to
address whether STAT5 is the preferred signal transducer of
FLT3 in AML and if presence of FLT3-ITD can be
predicted by quantification of pSTAT5 in leukemic blasts.
Materials and methods
Patients
A retrospective cohort of 75 patients with AML on first
diagnosis was included in this study. All newly diagnosed
patients with AML between 2005 and 2007 at the
University Hospital Basel, who had been fully evaluated
for cytogenetic alterations and molecular markers including
presence of FLT3-ITD, were considered if paraffin blocks
of bone marrow trephine biopsies were available and
adequately preserved for immunohistochemical analyses.
All cases were reclassified according to the most recent
WHO criteria [11]. Clinical and follow-up data were
obtained by reviewing the charts. Retrieval of tissue
and clinical data were performed according to data safety
laws. Of the 75 patients included in this study, 37 were
male (mean age 59; median age 57; range 26–95), and
38 were female (mean age 56; median 59; range 20–89).
The average follow-up time was 16.5 months (median
10; range 0–62 range). Within this time, 37 patients
passed away. Most of the patients (n=56) were treated
with curative intention (intensive chemotherapy alone, n=
23; intensive chemotherapy followed by autologous
hematopoietic stem cell transplantation, n=5; intensive
chemotherapy followed by allogeneic hematopoietic stem
cell transplantation, n=28). Nineteen patients, who did not
qualify for intensive treatment, received best supportive
care. Five of them were given hydroxyurea. The distribu-
tion of cases according to the WHO classification is
presented in Table 1.
Immunohistochemistry
Assessment of pSTAT expression profiles
Four-micrometer sections were cut to adhesive-coated
slides and stained using standard procedures. The precise
percentage of infiltrating blasts was identified by case-
specific markers using standard staining procedures. The
following antibodies were used: CD34 (M7165, DAKO,
final dilution 1:10), CD117 (A4502, DAKO, final dilution
1:80), CD68 (M7165, DAKO, final dilution 1:10), CD14
(MS-1080, Neomarkers, final dilution 1:10), CD163 (MS-
1103, Neomarkers, final dilution 1:5,000), and myeloper-
oxidase (A0398, DAKO, final dilution 1:10). Staining of
pSTAT1, pSTAT3, and pSTAT5 was performed as de-
scribed previously [4, 16] using commercially available
antibodies (pSTAT1: no. 9167; pSTAT3: no. 9145;
pSTAT5: no. 9359; all by Cell Signaling). The specificity
of the pSTAT3 and pSTAT5 stainings was corroborated by
preabsorption experiments with corresponding blocking
peptides (no. 1195, Cell Signaling, and no. 06-785-213045,
GenWay, respectively). One high-power field containing at
least 350 cells was assessed in each case to identify the
percentage of positive cells (i.e., cells displaying a distinct
nuclear staining). The slides were evaluated without
knowledge of clinical data or mutational status. Of the cases,
20% were reassessed by a second observer.
Assessment of coexpression of pSTAT5
and blast-specific markers
Six cases were double stained with the anti-pSTAT5
antibody and a blast-specific marker (either CD34 or
CD117) in order to prove that pSTAT5 is expressed in the
leukemic population.
For double stains of CD34 and pSTAT5, the antibody
for pSTAT5 was applied first and incubated at room
temperature overnight. The alkaline-phosphatase (AK-5000,
Vector Laboratories) technique was used for developing
with Substrat Kit III (SK-5300, Vector Laboratories) as
chromogen. The antibody against CD34 was consecu-
tively applied for an incubation time of 120 min at 37°C;
utilizing the avidin–biotin complex (AK-5100, Vector
Laboratories) either Nova-Red (SK-4800, Vector Laborato-
ries) or VIP (SK-4600, Vector Laboratories) served as
chromogens. For double stains of CD117 and pSTAT5,
antibodies against CD117 were applied first for an incubation
time of 120 min at 37°C; the reaction was visualized using the
alkaline-phosphatase method with the chromogen Substrat Kit
III. Antibodies against pSTAT5 were afterward incubated
overnight at room temperature; the labeling was visualized
with the aid of the avidin–biotin complex and Nova-Red as
chromogen.
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Cytogenetic analysis
Cytogenetic analyses were carried out at the Centre
Hospitalier Universitaire Vaudois in Lausanne (Unité
cytogénétique du cancer). Cell culture and chromosome
preparation were performed as reported previously [20].
Chromosomes were stained in G-bands. Karyotypes were
described according to the International System for Human
Cytogenetic Nomenclature [21].
FLT3-ITD and nucleophosmin (NPM1) mutations detection
All samples were analyzed for FLT3-ITD in exons 14 and
15 by reverse transcription-polymerase chain reaction
(RT-PCR) and agarose gel electrophoresis as previously
described [22]. RNA and cDNA were prepared from bone
marrow or from peripheral blood in patients with a dry tap.
cDNA (1 μg) was added to a total of 30-μl reaction mix
containing nuclease-free water (Catalyse AG), 15 mM
magnesium chloride (10× Puffer Qiagen), 10 mM dNTP
(Invitrogen), 10 μM forward primer, 10 μM reverse primer,
and Taq polymerase (Qiagen). The following primers were
used: 5′-AGC AAT TTA GGT ATG AAA GCC AG-3′ as
forward primer and 5′-CCT TCC CAA ACT CTA AAT
TTT CTC T-3′ as reverse primer (Microsynth). Preheating
of the samples at 95°C for 5′ was followed by amplification
for 35 cycles consisting of 30-s denaturation at 95°C, 30-s
annealing at 60°C, and 45-s elongation at 72°C. After
completion of these cycles, a final elongation of 5 min at
72°C was performed. Amplified PCR products were
supplemented with 6 μl loading buffer (Catalyse AG). Of
the final product, 15 μl were loaded on a 3% agarose gel
and analyzed by electrophoresis and ethidium bromide
staining. As a control, the cell line MV4-11 (ATCC) known
to contain the FLT3-ITD at 171 bp was included in every
analysis. The sensitivity of the assay was 10−2. Samples of
all AML patients with normal karyotypes, irrespective of
the disease subtype according to the WHO classification,
were analyzed for NPM1 mutations as described [23]. The
following primers were used: 5′-GCG CCA GTG AAG
AAA TCT ATA C-3′ as forward primer and 5′GGA CAA
CAT TTA TCA AAC ACG G-3′ as reverse primer (Micro-
synth). PCR products were analyzed on the ABI3130
Genetic Analyzer (Applied Biosystems). NPM1-positive
samples were sequenced to determine the type of mutation.
Statistical analysis
Statistical analyses were performed using SPSS version
15.0 (SPSS, Chicago, IL). Incomplete data were not
excluded from the tests. The degree of agreement between
the quantitative immunohistochemical values by the differ-
ent observers was evaluated by intra/interclass correlation
coefficients, using reliability Cronbach’s Alpha analysis.
The Fisher’s exact test was used to analyze differences in
case numbers distribution between groups. Mann–Whitney
or Kruskal–Wallis tests were applied as appropriate to
assess mean differences between groups. The prognostic
performance of the variables and determination of
optimal cutoff values was established by receiver
Table 1 Patient characteristics and distribution of FLT3-ITD
AML, classified according to WHO [11] Number of cases Cases with FLT3-ITD Casesa with NPM1 mutation
AML with recurrent genetic abnormalities
AML with t(8;21); RUNX1-RUNX1T1 4 0
AML with inv(16); CBFB-MYH11 4 0
Acute promyelocytic leukemia with t(15;17); PML-RARA 1 1
AML with myelodysplasia-related changes 21 1 3/4
Therapy-related AMLb 10 0 0/2
AML, not otherwise specified (NOS)
AML, NOS with normal karyotype 19 11 14/17
AML, NOS with single genetic aberrations 7 2
AML, NOS with complex aberrations 5 0
Others
Transformation of myeloproliferative neoplasmc 4 1 0/1
Total 75 16
a All 26 AML cases with normal karyotypes were tested for NPM1 mutations, irrespective of the disease subtype according to the WHO classification;
analysis succeeded in 24 cases; the results represent mutated cases out of all analyzable cases with normal karyotypes within the respective entity
b There were three additional acute promyelocytic leukemia with t(15;17) cases in this group, but considering the clinical history, these patients
had to be properly classified as therapy-related AML
cAll four cases were JAK2 wild type
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operating characteristic (ROC)-curves plotting sensitivity
vs 1-specificity with special considerations of the
respective area under the ROC (AUROC). The optimal
cutoff point was calculated using Youden’s index (Y),
denoting Y=sensitivity+specificity–1, since this method
can be applied to find the optimal cutoff value with the
highest sensitivity and specificity when there is no
particular requirement on sensitivity and/or specificity
[24]. Disease-specific survival was analyzed by the
Kaplan–Meier method and compared by the logrank test
in univariable modus and by the Cox regression analysis
in multivariable modus. Solely factors, which turned out
to be of prognostic significance in the univariable modus,
were entered into the multivariable analysis. Statistical
significance was defined as p<0.05 and corrected for
multiple testing, when necessary. Two-sided tests were
used throughout.
Results
Distribution of FLT3-ITD and NPM1 mutations
Altogether, 16 out of 75 cases (21%) showed FLT3-ITD
(males 11/38; females 5/37). The distribution of FLT3-ITD
among the different types of AML is displayed in Table 1.
NPM1 mutations were detected in 17/24 evaluable AML
patients with normal karyotypes (Table 1); 16 of these were
type A mutations, and 8 were observed in FLT3-ITD cases.
Immunohistochemistry
Immunohistochemical stainings were evaluable in 65 cases
for pSTAT1, 65 cases for pSTAT3, and 60 cases for
pSTAT5 (Fig. 1a–f). pSTAT3 and pSTAT5 stainings could
be fully oppressed by preabsorption with the respective
blocking peptides. Blasts were considered to express the
respective marker if their nuclear staining was clearly
detectable against the background. Positivity in nuclei of
lymphocytes, neutrophils, erythroid precursors, and vascu-
lar walls served as an internal control (Fig. 1a–f). The
interclass correlation for interobserver variability was
excellent for pSTAT5 (p=0.002, alpha=0.740), good for
pSTAT1 (p=0.006, alpha=0.651), and acceptable for
pSTAT3 (p=0.05, alpha=0.517).
pSTAT5 was expressed in a mean 11±13% blasts
(median 2.5%, range 0.8–39%) in AML with FLT3-ITD
as opposed to 0.7±0.9% (median 0.4%, 0–3.7%) in cases
without FLT3 abnormalities (pMann–Whitney-U<0.0001), but
there were no significant differences for pSTAT1 or
pSTAT3, respectively (Fig. 2, Table 2). Importantly,
pSTAT5 was expressed in only 0.2±0.3% blasts in the
three analyzable AML transformations of myeloprolifera-
tive neoplasm cases; one AML transformation of myelo-
proliferative neoplasm case with FLT3-ITD was not
analyzable for pSTAT5. Double staining of pSTAT5 and
the blast-specific markers CD34 or CD117 showed coex-
pression of the two markers, proving the correct labeling of
blasts by the antibody against pSTAT5 (Fig. 1f).
The AUROC of the predictive value of pSTAT5
expression for FLT3-ITD was 0.901 (95% confidence
interval 0.822–0.980) with a cutoff with both maximum
specificity (73%) and sensitivity (100%) suggested by the
Youden’s index of >0.8% (Fig. 3). The positive predictive
value (PPV) for the presence of FLT3-ITD in AML cases
with expression of pSTAT5 in >0.8% of blasts was 57%;
the negative predictive value (NPV) was 100%. Applying
Fig. 1 a pSTAT1 expression in AML; note scattered positive
neutrophils and lymphocytes as well as negative megakaryocytes;
immunoperoxidase stain, 200×. b pSTAT3 expression in AML; note
scattered positive blasts; immunoperoxidase stain, 200×. c, d pSTAT5
expression in erythroid precursor islet and in microvascular walls of
FLT3 wild-type AML; immunoperoxidase stain, 200×. e Abundant
pSTAT5 expression in FLT3-ITD AML; immunoperoxidase stain,
200×. f CD117 (blue)/pSTAT5 (red) double stain showing colocaliza-
tion of signals; immunoperoxidase stain, 640×
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this cutoff, all 12 FLT3-ITD cases were identifiable, while
seven out of 48 cases without FLT3-ITD also expressed
pSTAT5 in >0.8% of blasts (pFisher’s<0.001). The cutoff
with highest specificity was 4.7% with a PPV of 100%
(since not a single case without FLT3-ITD expressed
pSTAT5 in >4.7% of blasts) and a NPV of 86%.
Clinical outcome
Survival data were available for all patients. Thirty-seven
patients died within 16 months with a mean survival of
6.1 months. The univariable analysis of clinical parameters
(age below vs equal/above 60 years, sex), disease subtype
according to the WHO classification, FLT3 status, NPM1
status, expression of pSTAT1, 3, and 5, and type of therapy,
for their prognostic significance showed that the disease
subtype according to the WHO classification (p<0.001),
age at diagnosis (p<0.001), and therapy type (p<0.001)
predicted survival, while the other parameters showed no
influence. Only in AML not otherwise specified (NOS)
with normal karyotype (n=19, all but two treated in
curative intention) presence of FLT3-ITD but not of
NPM1 mutations turned out to be of prognostic signifi-
cance (p=0.033; Fig. 4). Consideration of the NPM1
status in our series of AML, NOS with normal karyotype
was of no additional prognostic value neither in all cases
nor in cases split according to their FLT3 status. This was
also the case for the prognostic significance NPM1
Fig. 3 ROC curve indicating a significant discriminatory potential
of the amount of pSTAT5 expressing blasts for predicting FLT3-
ITD. Note that the dark ROC curve never crosses the dotted
reference line (corresponding to random guess or variable without
diagnostic capability) and that the AUROC is 0.901, indicating that
consideration of pSTAT5 is as 40% more accurate to predict
presence/absence of FLT3-ITD as a random guess (for more details,
see [24]). The curve point at a sensitivity of 1 (100%) and specificity
of 0.73 (73%; 1-specificity=0.27) is at greatest distance away from
the reference line. Considering increased pSTAT5 expressing blasts,
these coordinates correspond to an optimal cutoff for the prediction
of FLT3-ITD of >0.8%
Fig. 2 Boxplot of pSTAT5 expression in FLT3 wild type (wt) and
mutated (ITD) acute myelogenous leukemia cases; pMann–Whitney-U<
0.0001
Table 2 Expression of pSTAT1, 3, and 5 with respect to FLT3-ITD
status
Mean number of positive blasts per HPFa
pSTAT1 pSTAT3 pSTAT5
FLT3 wild type 9±21 (50) 38±39 (45) 21±24 (48)
FLT3-ITD 6±8 (15) 46±42 (10) 167±262 (12)
p value ns ns 0.004
aHPF high-power field, i.e., 0.177 mm2 , ns not significant
Number of evaluable cases is shown in brackets
Fig. 4 Kaplan–Meier survival curves of AML, not otherwise
specified cases with normal karyotype with respect to the FLT3
status; the p value has been calculated by applying the logrank test.
Two out of eight AML patients without FLT3-ITD died (mean
survival 44 months, median not reached), while seven out of 11 AML
patients with FLT3-ITD died (mean survival 16 months, median
6 months; p=0.033)
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mutations in AML with myelodysplasia-related changes
with normal karyotypes.
When the prognostic parameters were assessed in a
multivariable manner, only type of therapy (p=0.03) and
age (p<0.001) retained their statistical significance for all
AML. In a multivariable model in AML, NOS with normal
karyotype FLT3-ITD turned to be an age- and therapy type-
independent negative prognostic factor, even after correc-
tion for multiple testing (p=0.026, relative risk 7.62, 95%
confidence interval 1.28–45.34).
Discussion
Here, we were able to show that assessment of pSTAT1-,
3-, and, particularly, pSTAT5-positive blasts is reproducibly
possible in formalin-fixed paraffin-embedded trephine bone
marrow biopsies by immunohistochemistry. Of the markers
analyzed, assessment of pSTAT3 showed only acceptable
interobserver reproducibility, primarily due to the presence
of weakly stained blasts, which were variably taken into
consideration by the observers. This finding should be
considered in future in situ bone marrow studies addressing
pSTAT3 expression.
In addition, we demonstrated that pSTAT5 expression
is significantly correlated to FLT3-ITD and proved by
double labeling that pSTAT5 is specifically expressed in
myeloid blasts (Fig. 1f), indicating that, similarly to
normal hematopoiesis, STAT5 is highly likely the pre-
ferred second messenger of FLT3-mediated cell signaling.
The distribution of FLT3-ITD AML cases (21% of the
studied samples) and the observed strong prognostic
impact of FLT3-ITD in AML with normal karyotypes are
in line with the literature, reporting such mutations in
approximately 25% of AML and association with an
adverse clinical outcome with poor overall survival and a
higher risk of relapse, particularly in AML with normal
karyotypes [5, 6]. These basic characteristics of our cohort
additionally point toward its representativeness.
FLT3 and its downstream STAT-related pathways play a
fundamental role in AML [14, 15]. Therefore, assessment
of FLT3 mutations as well as addressing their functional
significance, e.g., by measurement of pSTAT5 might be
important. Analysis of pSTAT has been attempted by
different methodologies such as flow cytometry [25],
electrophoretic mobility shift assays [15, 26], and western
blot analysis [27, 28]. Interestingly, the percentage of cases
with pSTAT expression varied between 7% [26] and 95%
[28]. Some discrepancies can probably be attributed to the
applied methodologies as well as the sensitivity and
specificity of the antibodies. However, the specificity of
the anti-pSTAT5 antibody applied in this study has been
proven previously [4, 16] and additionally in the present
study by preabsorption with a corresponding blocking
peptide. Addressing the strengths and drawbacks of western
blot analysis, samples may contain other cells, such as
vascular structures or erythroid precursors, which can also
express pSTAT5, as shown in Fig. 1c, d. Association of
pSTAT5 expression and FLT3-ITD in AML is obviously
only relevant for pSTAT5 expression in blasts. Identifica-
tion of in situ pSTAT5 expression in blasts seems to be
possible only when the microtopography of the evaluated
tissue sample is preserved, which is the case in our technique,
but not in western blot or electrophoretic mobility shift assays.
Assessment of STAT5 gene expression by quantitative PCR
would not be helpful as well since the phosphorylated
(active) protein amount and its microtopographic distribution
is of relevance. Importantly, on the functional level, it has
been clearly shown that mutations of FLT3 result in the
strong activation of STAT5 [2, 29], and vice versa,
constitutive phosphorylation of STAT5 can efficiently be
downregulated by a FLT3 tyrosine kinase inhibitor [30].
Our findings support the hypothesis that FLT3 mutations
lead to an activation of STAT5, which in turn can be
assessed in order to predict the FLT3 status. Furthermore,
both FLT3 and STAT5 have been identified as potential
new therapeutic targets for treatment of patients with AML
[31]. In particular, combining FLT3 inhibitors and agents,
such as antisense nucleotides, small molecular inhibitors, or
shRNA, targeting STAT and STAT-related pathways has
been recommended by some authors [32]. Therefore,
simultaneous assessment of both FLT3 mutation status
and STAT5 expression and phosphorylation status might be
required in the future for selecting AML patients for
targeted therapies.
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